Trials / Completed
CompletedNCT01875380
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
A Phase II Study of Single-agent Regorafenib in the First Line Treatment of Frail and/or Unfit for Polychemotherapy Patients With Metastatic Colorectal Cancer (mCRC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of single-agent regorafenib in the first line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2013-06-11
- Last updated
- 2017-08-01
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT01875380. Inclusion in this directory is not an endorsement.